Thrombophilia screening testing is a specialized laboratory evaluation designed to identify inherited and acquired disorders that predispose individuals to abnormal blood clot formation. This comprehensive testing panel combines functional coagulation assays, immunological tests, and molecular genetic analysis to detect deficiencies of natural anticoagulants, antiphospholipid antibodies, and thrombophilia-associated gene mutations. Understanding the scope, methodology, and clinical application of thrombophilia screening is essential for the prevention and management of venous thromboembolism and recurrent pregnancy loss.
Technical Overview
Thrombophilia refers to a group of hemostatic disorders—either inherited or acquired—that disrupt the balance between procoagulant and anticoagulant mechanisms, resulting in a hypercoagulable state and an increased risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Thrombophilia screening testing is a systematic laboratory evaluation that identifies the underlying causes of this hypercoagulability through a multi-dimensional analytical approach.
Hereditary thrombophilia is commonly associated with factor V Leiden (FVL) mutation, prothrombin G20210A gene mutation, methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms, and deficiencies of natural coagulation inhibitors such as antithrombin (AT), protein C (PC), and protein S (PS). Acquired thrombophilia is predominantly represented by antiphospholipid syndrome (APS), characterized by the persistent presence of lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta-2 glycoprotein I antibodies (anti-β2GPI). Elevated factor VIII activity, hyperfibrinogenemia, and hyperhomocysteinemia are additional risk markers frequently incorporated into screening panels.
Modern thrombophilia screening integrates functional coagulation assays, chromogenic and immunological quantification, and molecular genetic detection, typically performed in accredited third-party laboratories or specialized hemostasis laboratories operating under quality management systems compliant with ISO 15189 and ISO/IEC 17025. Test procedures follow established guidelines issued by standards organizations such as CLSI (Clinical and Laboratory Standards Institute) and relevant national standards, ensuring analytical accuracy, precision, and clinical reliability.
Testing Samples
Citrated Platelet-Poor Plasma
Functional coagulation assays, including activated partial thromboplastin time (APTT)-based screening tests, protein C and protein S activity assays, antithrombin activity assays, and lupus anticoagulant testing, require platelet-poor plasma collected in 3.2% sodium citrate tubes at a 9:1 blood-to-anticoagulant ratio. For lupus anticoagulant testing, double centrifugation is required to achieve a platelet count below 10 × 10⁹/L, as residual platelets release phospholipids that may cause false-negative results. Samples should be tested within 4 hours when maintained at room temperature, or centrifuged and frozen at −70 °C for extended storage, in accordance with CLSI H21 guidelines.
Serum Samples
Serum collected in plain tubes or separator tubes is used for immunological tests such as anticardiolipin antibodies, anti-β2GPI antibodies, and homocysteine quantification. Samples should be allowed to fully clot, centrifuged promptly to remove cellular components, and stored at 2–8 °C for short-term analysis or frozen at −20 °C or below for longer storage to preserve antibody integrity.
EDTA Whole Blood for Genetic Analysis
Molecular testing for factor V Leiden (F5 G1691A), prothrombin (F2 G20210A), and MTHFR (C677T and A1298C) polymorphisms requires peripheral whole blood collected in EDTA anticoagulant tubes. Genomic DNA is extracted from leukocytes, and samples should be transported under temperature-controlled conditions. EDTA blood is stable at 2–8 °C for several days prior to DNA extraction, ensuring high-quality template material for amplification-based assays.
Pre-Analytical Considerations
- Testing should ideally be performed outside the acute thrombotic phase, as acute thrombosis and inflammation transiently consume and alter coagulation proteins, causing acquired deficiencies.
- Anticoagulant therapy (heparin, warfarin, direct oral anticoagulants) significantly interferes with functional assays; samples should be collected before initiation of therapy or after an appropriate washout period.
- Heparin contamination must be excluded, particularly for antithrombin and APTT-based assays.
- Pregnancy, estrogen therapy, and liver disease can physiologically reduce protein S and antithrombin levels and should be documented during interpretation.
- Confirmation of persistent antiphospholipid antibody positivity requires repeat testing at least 12 weeks apart, as defined by accepted laboratory classification criteria.
Testing Items
A comprehensive thrombophilia screening panel typically encompasses the following categories of analytes:
- Natural coagulation inhibitor panel: antithrombin (AT) activity and antigen, protein C (PC) activity and antigen, total and free protein S (PS) antigen, and protein S activity.
- Activated protein C resistance (APC-R): functional screening for factor V Leiden–associated resistance, typically expressed as a normalized sensitivity ratio.
- Molecular genetic markers: factor V Leiden mutation (F5 G1691A), prothrombin gene mutation (F2 G20210A), MTHFR C677T and A1298C polymorphisms, and extended gene panels covering PAI-1 (SERPINE1) 4G/5G, fibrinogen beta-chain (FGB) −455 G>A, factor XIII V34L, and platelet receptor polymorphisms where indicated.
- Antiphospholipid antibody panel: lupus anticoagulant (LA) by diluted Russell viper venom time (DRVVT) and silica clotting time (SCT) screening and confirmation, anticardiolipin antibodies (IgG and IgM), and anti-beta-2 glycoprotein I antibodies (IgG and IgM).
- Procoagulant and adjunctive markers: factor VIII activity, fibrinogen concentration, homocysteine, D-dimer as a marker of activation, and routine coagulation screening (PT, APTT, thrombin time, fibrinogen).
Testing Methods
Thrombophilia screening employs a combination of functional, immunological, and molecular techniques, each selected according to the analyte and the clinical question addressed.
- Clot-based functional assays: PT and APTT are performed on automated coagulation analyzers using the clot-detection principle. APC-R is measured using APTT-based assays with and without activated protein C reagent, and protein C activity may be determined by clotting assays, following CLSI H47 and related guidance.
- Chromogenic substrate assays: antithrombin and protein C activities are quantified using synthetic chromogenic substrates, in which the enzymatic activity of the target protein cleaves the substrate to release a colored product measured photometrically. This method offers high precision and minimal interference and is recognized as the reference approach for AT and PC quantification.
- Immunological assays: free protein S antigen, anticardiolipin antibodies, and anti-β2GPI antibodies are quantified by enzyme-linked immunosorbent assay (ELISA) or latex-enhanced immunoturbidimetric methods on automated platforms, with calibration against international reference preparations where available.
- Lupus anticoagulant detection: performed according to CLSI H60 and international consensus guidelines using a two-step algorithm—screening assays (DRVVT, SCT) to detect prolonged phospholipid-dependent clotting, mixing studies to exclude factor deficiency, and confirmation assays with excess phospholipid to demonstrate phospholipid dependence. Results are expressed as normalized ratios.
- Molecular genetic testing: genomic DNA is amplified by polymerase chain reaction (PCR), and genotype determination is achieved through real-time PCR with fluorescent hydrolysis probes, PCR-restriction fragment length polymorphism analysis, Sanger sequencing, or next-generation sequencing (NGS) panels covering multiple thrombophilia-associated loci simultaneously.
- Homocysteine quantification: measured by enzyme immunoassay, high-performance liquid chromatography (HPLC), or liquid chromatography-tandem mass spectrometry (LC-MS/MS), with samples processed promptly to prevent ex vivo increases in homocysteine concentration.
All analytical procedures are subject to internal quality control and external quality assessment programs. Reference intervals are established and verified in accordance with CLSI C28, and molecular assays are validated for analytical sensitivity, specificity, and accuracy prior to clinical implementation.
Applications
Thrombophilia screening testing serves multiple clinical and preventive purposes across a range of patient populations:
- Unprovoked or recurrent venous thromboembolism: identifying hereditary or acquired thrombophilia in patients with DVT or PE occurring at a young age, at unusual sites, or without precipitating risk factors.
- Recurrent pregnancy loss and adverse pregnancy outcomes: evaluating obstetric antiphospholipid syndrome in women with recurrent early pregnancy loss, fetal death, severe pre-eclampsia, or placental insufficiency, guiding prophylactic anticoagulation and pregnancy management.
- Family screening of first-degree relatives: cascade testing for known mutations or deficiencies in relatives of affected individuals, enabling risk stratification and preventive counseling.
- Pre-treatment risk assessment: evaluating thrombotic risk before initiating estrogen-containing contraceptives, hormone replacement therapy, or assisted reproduction protocols, particularly in women with a personal or family history of thrombosis.
- Perioperative and high-risk scenario evaluation: risk assessment before major orthopedic surgery, prolonged immobilization, or long-haul travel in individuals with a suggestive personal or family history.
- Duration of anticoagulation decisions: laboratory findings, particularly antiphospholipid antibodies and natural inhibitor deficiencies, inform the intensity and duration of anticoagulant therapy following a first thrombotic event.
- Clinical research and epidemiological studies: supporting investigation of genotype–phenotype correlations, prevalence studies of thrombophilic markers, and evaluation of preventive intervention strategies.
FAQ
Who should consider thrombophilia screening testing?
Screening is recommended for individuals with unprovoked or recurrent VTE, thrombosis at a young age (typically before 45–50 years), thrombosis at unusual anatomical sites, recurrent pregnancy loss or obstetric complications, or a strong family history of thrombosis. Testing is also considered before high-risk interventions such as estrogen therapy in selected patients.
When is the optimal time for testing?
Ideally, testing should be performed at least 3 to 6 months after an acute thrombotic event and at least 2 weeks after discontinuation of anticoagulant therapy, since acute phase reactions and anticoagulants significantly alter functional assay results. Genetic tests are not affected by the acute phase or anticoagulation and may be performed at any time.
Can testing be performed while taking anticoagulants?
Heparin and direct oral anticoagulants interfere with clot-based functional assays and lupus anticoagulant tests, while warfarin reduces protein C and protein S levels. Where anticoagulation cannot be interrupted, genetic testing and certain immunological assays remain valid, and functional testing may be deferred or interpreted with appropriate caution.
What does a positive result mean?
A positive result indicates the presence of a thrombophilic marker associated with an elevated risk of thrombosis, but it does not mean that a clot will inevitably occur. Results must be interpreted in the context of personal and family history, transient risk factors, and current clinical status, ideally with the support of a hematologist or thrombosis specialist.
How long does testing take?
Functional and immunological assays are typically completed within 3 to 5 working days. Molecular genetic testing generally requires 7 to 10 working days, depending on the complexity of the panel and the sequencing method applied. Confirmation testing for antiphospholipid antibodies requires a second sample collected at least 12 weeks after the initial positive result.
Is a single abnormal result sufficient for diagnosis?
No. Acquired conditions such as pregnancy, liver disease, inflammation, and vitamin K deficiency can transiently reduce natural inhibitor levels. Persistent abnormalities confirmed on repeat testing, together with consistent clinical findings, are required for a definitive laboratory diagnosis, particularly for antiphospholipid syndrome classification.